This looks like a very relevant report. For anyone that can actually afford to buy it!
https://www.digitaljournal.com/pr/news/knee-osteoarthritis-emerging-and-marketed-drugs-assessment-2023-updates-clinical-and-non-clinical-trials-evaluation-latest-fda-ema-and-pmda-approvals-treatment-outlook-competitive-landscape-and-key-companies
research reports and media, page-3635
-
- There are more pages in this discussion • 749 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
24.5¢ |
Change
0.010(4.26%) |
Mkt cap ! $85.70M | |||
| Open | High | Low | Value | Volume |
| 24.0¢ | 25.5¢ | 24.0¢ | $32.79K | 133.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 20314 | 24.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 25.0¢ | 31760 | 5 |
View Market Depth
| Last trade - 10.50am 12/08/2024 (20 minute delay) ? |
| PAR (ASX) Chart |